Primary Sjögren's syndrome-associated immune thrombocytopenia: from pathogenesis to treatment. [PDF]
Liu C, Zheng Z, He T, Zhang G, Fu G.
europepmc +1 more source
Novel use of telitacicept in primary immune thrombocytopenia: a case report. [PDF]
Wang Y +6 more
europepmc +1 more source
Integrated transcriptomic, single‐cell, pseudotime, cell–cell communication, human tissue, and in vivo analyses define a dynamic four‐gene axis across the MASLD continuum. Progressive CYP2C19 downregulation and AKR1B10, COL1A2, and SPP1 upregulation link metabolic dysfunction to disease progression, while AKR1B10 knockdown or CYP2C19 overexpression ...
Kejun Liu +5 more
wiley +1 more source
Chromaffin Versus Platelet Granules: What We Have Learned From Chromaffin Cells for Human Studies. [PDF]
Borges R.
europepmc +1 more source
Neural cell–derived small extracellular vesicles (sEVs) are emerging as pivotal mediators in neurodegenerative diseases, exerting both pathogenic and therapeutic functions. This review synthesizes current evidence on how sEVs from distinct neural cell types regulate neurodegeneration, neuroprotection, biomarker discovery, and targeted drug delivery ...
Muhammad Waqas Salim +4 more
wiley +1 more source
Platelet glycoprotein VI modulates leukocyte characteristics in sepsis-induced systemic inflammatory response in male mice. [PDF]
Corken A, Ware J, Thakali KM.
europepmc +1 more source
ABSTRACT Electrochemical biosensors enable the accurate and timely detection of clinical biomarkers, improving healthcare and precision medicine. MXene nanosheets, a class of 2D transition metal carbides, nitrides, and carbonitrides, are promising materials for developing next‐generation electrochemical biosensors due to their unique physicochemical ...
Muhsin Ali +4 more
wiley +1 more source
Key role of the endothelium in lung ischemia-reperfusion injury: What the clinician needs to know. [PDF]
Besnier E +3 more
europepmc +1 more source
Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann +15 more
wiley +1 more source
From Circulation to Regeneration: Blood Cell Membrane-Coated Nanoparticles as Drug Delivery Platform for Immune-Regenerative Therapy. [PDF]
Kim YA, Lee MH, Sohn HS, Kim HY.
europepmc +1 more source

